Search

Displaying results 5331 - 5340 of 8698 in total
  1. Drug

    Oxitropium

    go.drugbank.com/drugs/DB12086
    Investigational

    Oxitropium has been investigated for the treatment of Pulmonary Disease, Chronic Obstructive.

    Categories: Drugs for Obstructive Airway Diseases
  2. Drug

    AVR-RD-01

    go.drugbank.com/drugs/DB17651
    Investigational

    AVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc. … AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968]

  3. Drug

    Seproxetine

    go.drugbank.com/drugs/DB06731
    Experimental

    It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  4. Drug

    Enrofloxacin

    go.drugbank.com/drugs/DB11404
    InvestigationalVet approved

    Enrofloxacin is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation. Enrofloxacin is approved by the FDA for its veterinary use. … Due to the identification of fluoroquinolone-resistant strains of _Campylobacter_, in September 2005, the FDA withdrew the approval of enrofloxacin for its use in water to treat flocks of poultry.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inhibitors
  5. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194] It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

    Categories: Colony Stimulating Factor-1 Receptor Blocker
  6. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists
  7. Drug

    QR-333

    go.drugbank.com/drugs/DB05533
    Investigational

    QR-333 has been investigated as a treatment for diabetic peripheral neuropathy. … concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder that can

  8. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes. … ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR).

  9. Drug

    Girentuximab

    go.drugbank.com/drugs/DB05304
    Investigational

    Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).

  10. Drug

    Quinagolide

    go.drugbank.com/drugs/DB09097
    ApprovedWithdrawn

    Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. … Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States.

    Categories: Dopamine D2 Receptor Agonists